LAST UPDATE : 18-03-2024
Professor Olivier Mimoz, head of the emergency department at Hôpital Universitaire de Poitiers, France, and principal investigator of the CLEAN3 trial, summarizes the results of the trial published in the Lancet Infectious Diseases. The trial showed that the use of the BD vascular care solution resulted in fewer PIVC failures compared with the standard group (34.8% vs. 47.5%. respectively) and extended the median time between catheter insertion and failure (50.4 hours vs 30.0 hours, respectively).
February 6, 2023
The activated hyperlink may be to a third-party website. Clicking on the link may allow third parties to collect or share data about you. We do not control these third-party websites and are not responsible for their privacy statements. When you leave this website, we encourage you to read the privacy notice of every website you visit.
Where the website is managed by another BD company, please note that it may be governed by different laws and policies, and may feature products and services that are not available locally. Please contact your local BD representative if you have any questions or should you require further support.